Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: In vitro and in vivo evaluations

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 6, 2005, Pages 463-474

  Majumdar, Soumyajit ^a,b   Nashed, Yasser E ^a,c   Patel, Kunal ^a   Jain, Ritesh ^a   Itahashi, Motoki ^d   Neumann, Donna M ^d   Hill, James M ^d   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c AMGEN INC   (United States)

^d LSU EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; GLYCYLVALYLGANCICLOVIR; OCTANOL; PRODRUG; TRIFLURIDINE; TYROSYLVALYLGANCICLOVIR; UNCLASSIFIED DRUG; VALYLTYROSYLGANCICLOVIR; VALYLVALYLGANCICLOVIR; VIDARABINE; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; KERATITIS; LIPOPHILICITY; MALE; NONHUMAN; PARTITION COEFFICIENT; RABBIT;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEAL STROMA; DIPEPTIDES; DRUG STABILITY; EPITHELIUM, CORNEAL; ESTERS; GANCICLOVIR; HERPESVIRUS 1, HUMAN; INSTILLATION, DRUG; KERATITIS, HERPETIC; MALE; MOLECULAR STRUCTURE; OPHTHALMIC SOLUTIONS; PERMEABILITY; PRODRUGS; RABBITS; SOLUBILITY;

EID: 30544437062     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.463     Document Type: Article

References (30)

1. Remeijer, L., Osterhaus, A., and Verjans, G. Human herpes simplex virus keratitis: The pathogenesis revisited. Ocul. Immunol. Inflamm. 12:255-285, 2004.
2. Kaufman, H.E. Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc. Soc. Exp. Biol. Med. 109:251-252, 1962.
3. Lass, J.H., Langston, R.H., Foster, C.S., et al. Antiviral medications and corneal wound healing. Antiviral Res. 4:143-157, 1984.
4. Imperia, P.S., Lazarus, H.M., Dunkel, E.G., et al. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res. 9:263-272, 1988.
5. la Lau, C., Oosterhuis, J.A., Versteeg, J., et al. Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial. Doc. Ophthalmol. 50:287-290, 1981.
6. Hovding, G. A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial. Acta. Ophthalmol. (Copenh). 67:51-54, 1989.
7. Colin, J., Hoh, H.B., Easty, D.L., et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 16:393-399, 1997.
8. Hoh, H.B., Hurley, C., Claoue, C., et al. Randomized trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: A multicenter study. Br. J. Ophthalmol. 80:140-143, 1996.
9. Andrei, G., Snoeck, R., Schols, D., et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur. J. Clin. Microbiol. Infect. Dis. 10:1026-1033, 1991.
10. Shigeta, S., Konno, K., Baba, M., et al. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. J. Infect. Dis. 163:270-275, 1991.
11. Balzarini, J., Degreve, B., Andrei, G., et al. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene. Ther. 5:419-426, 1998.
12. Majumdar, S., Tirucherai, G.S., Pal, D., et al.. Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS PharmSci. 5:E15, 2003.
13. Majumdar, S., Gunda, S., and Mitra A.K. Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine. Curr. Eye Res. 26:175-183, 2003.
14. Tirucherai, G.S., and Mitra, A.K. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSci. 4:E45, 2003.
15. Dias, C.S., Anand, B.S., and Mitra, A.K. Effect of mono- and di-acylation on the ocular disposition of ganciclovir: Physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J. Pharm. Sci. 91:660-668, 2002
16. Duvvuri, S., Majumdar, S., and Mitra, A.K. Drug delivery to the retina: Challenges and opportunities. Exp. Opin. Biol. Ther. 3:45-56, 2003.
17. Majumdar, S., Duvvuri, S., and Mitra, A.K. Membrane transporter/receptor- targeted prodrug design: Strategies for human and veterinary drug development. Adv. Drug Deliv. Rev. 56:1437-1452, 2004.
18. +/peptide symporter PepT1 expressed in Xenopus laevis oocytes. J. Membr. Biol. 155:247-256, 1997.
19. Balimane, P.V., Tamai, I., Guo, A., et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250:246-251, 1998.
20. Hoglund, M., Ljungman, P., and Weller, S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J. Antimicrob. Chemother. 47:855-861, 2001.
21. Reusser, P. Oral valganciclovir: A new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Exp. Opin. Invest. Drugs. 10:1745-1753, 2001.
22. Anand, B., Nashed, Y., and Mitra, A.K. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity, and transport across rabbit cornea. Curr. Eye Res. 26:151-163, 2003.
23. Anand, B.S., Hill, J.M., Dey, S., et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest. Ophthalmol. Vis. Sci. 44:2529-2534, 2003.
24. Anaizi, N.H., Dentinger, P.J., and Swenson, C.F. Stability of valganciclovir in an extemporaneously compounded oral liquid. Am. J. Health Syst. Pharm. 59:1267-1270, 2002.
25. Henkin, C.C., Griener, J.C., and Ten Eick, A.P. Stability of valganciclovir in extemporaneously compounded liquid formulations. Am. J. Health Syst. Pharm. 60:687-690, 2003.
26. Harnden, M.R., and Serafinowska, H.T. Synthesis and properties of s-phosphates of some antiviral acyclonucleosides. Nucleosides Nucleotides 13:903-913, 1994.
27. Majumdar, S., Macha, S., Nashed, Y., et al. Expression of peptide transporters on the rabbit retina: A strategy to improve retinal delivery of ganciclovir. Lett. Drug Des. Discov. 1:73-77, 2004.
28. Nashed, Y.E., and Mitra, A.K. Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir. Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 59:2033-2039, 2003.
29. Millikin, G.A., and Johnson, D.E. Analysis of Messy Data. New York: Van Nostrand Reinhold, 1984:413-423.
30. Edwards, D., and Berry, J.J. The efficiency of simulation-based multiple comparisons. Biometrics 43:913-928, 1987.